

To Whom It May Concern

KYORIN Co.,Ltd

**Launch of Ulcerative Colitis and Crohn's Disease Therapeutic Agent
Pentasa® Tablets 500**

Tokyo—October 1,2008,KYORIN Co., Ltd. Announces that its wholly owned subsidiary, KYORIN Pharmaceutical Co., Ltd.(Headquarters :Tokyo, President :Itaru Kojo) launched today Pentasa® Tablets 500 as an additional formulation to the Pentasa®250 (generic name :mesalazine) already on the market.

Since July 1996, KYORIN Pharmaceutical Co., Ltd. and Nisshin Kyorin Pharmaceutical Co., Ltd. both have marketed Pentasa® Tablets 250 and have contributed to the treatment of ulcerative colitis and Crohn's disease.

Pentasa® Tablets 500 lessen the burden on patients by reducing the number of tablets currently marketed Pentasa® Tablets 250 that are administered per day. Pentasa® Tablets 500 were developed for the purpose of improving adherence* as well as QOL.

To distinguish them from the round Pentasa® Tablets 250, Pentasa® Tablets 500 came in a capsule form.

Inflammatory bowel diseases (ulcerative colitis and Crohn's disease) are intractable diseases that hinder social interaction, causing frequent diarrhea and melena. The causes have not been identified and there is no radical treatment. Therefore, the therapeutic goals are suppressing symptoms in the active phase, alleviating the symptoms and keeping the symptoms in a relieved state with the use of mesalazine drugs like Pentasa and steroids.

On October 1, 2008, KYORIN Pharmaceutical Co., Ltd. merged Nisshin Kyorin Pharmaceutical Co., Ltd. into KYORIN Pharmaceutical Co., Ltd. we will exclusively market Pentasa® Tablets 250, Pentasa® Enema 1g and Pentasa® Tablets 500 and will make an ongoing contribution to the treatment of inflammatory bowel diseases by providing the latest information, including peripheral information.

* Adherence is more about patients' taking responsibility in following the appropriate procedures for the therapy they receive, than it is about following the directions of physicians or pharmacists.

For further information, contact:

KYORIN Co.,Ltd

Management Planning Department

Telephone:+81-3-3293-3414

Fax:+81-3-3293-3454

Products Plofile

1.Brand name	Pentasa® Tablets 500	Pentasa® Tablets 250
2.Nonproprietary name	Mesalazine	Mesalazine
3.Indication	Ulcerative colitis (excluding severe cases) and Crohn's disease	Ulcerative colitis (excluding severe cases) and Crohn's disease
4.Dosage and Administration	<p>Ulcerative Colitis</p> <p>Normally, for adult patients, a daily dose of 1500 mg is divided into three doses and is administered orally after meals. The dose may be decreased or increased according to the age and symptoms while the upper limit is 2250 mg per day.</p> <p>Normally, for infant patients, a daily dose of 30 to 60 mg/kg of mesalazine is divided into three doses and administered orally after meals. The dose may be decreased or increased according to the age and symptoms while the upper limit is 2250 mg per day.</p> <p>Crohn's Disease</p> <p>Normally, for adult patients, a daily dose of 1500-3000 mg is divided into three doses and is administered orally after meals. The dose may be decreased according to the age and symptoms.</p> <p>Normally, for infant patients, a daily dose of 40 to 60 mg/kg of mesalazine is divided into three doses and administered orally after meals. The dose may be decreased or increased according to the age and symptoms.</p>	<p>Ulcerative Colitis</p> <p>Normally, for adult patients, a daily dose of 1500 mg is divided into three doses and is administered orally after meals. The dose may be decreased or increased according to the age and symptoms while the upper limit is 2250 mg per day.</p> <p>Normally, for infant patients, a daily dose of 30 to 60 mg/kg of mesalazine is divided into three doses and administered orally after meals. The dose may be decreased or increased according to the age and symptoms while the upper limit is 2250 mg per day.</p> <p>Crohn's Disease</p> <p>Normally, for adult patients, a daily dose of 1500-3000 mg is divided into three doses and is administered orally after meals. The dose may be decreased according to the age and symptoms.</p> <p>Normally, for infant patients, a daily dose of 40 to 60 mg/kg of mesalazine is divided into three doses and administered orally after meals. The dose may be decreased or increased according to the age and symptoms.</p>
5.NHI price	¥118.80 per tablet	¥59.40 per tablet
6.Packaging	PTP 100 tablets	PTP 100,500 tablets

Reference:

1.Bland name	Pentasa [®] Enema 1g
2.Indications	Ulcerative colitis (excluding severe cases)
3.Dosage and Administration	Normally, for adult patients, a bottle (1 g mesalazine) as a daily dose is injected through the rectal route. The dose may be decreased according to the age and symptoms.
4.NHI price	¥872.90 per bottle (1g)
6.Packaging	100 ml ×7